
2026 GLP-1 cost guide
Semaglutide used to be considerably more expensive for many cash-pay patients. In 2026, competition, manufacturer self-pay programs and lower-priced clinic programs have changed the market substantially.
Medically reviewed by Dr. Timothy Mackey
Medical Director · Pricing reviewed September 2026

Current semaglutide-related pricing spans a wide range. Published cash-pay compounded programs can begin around $150 per month and rise toward $300 or more as dose increases. Other physician-supervised or bundled GLP-1 programs can cost roughly $300–$500+ per month depending on what is included. Brand-name Wegovy has separate manufacturer self-pay pricing.
Historically, uninsured patients could encounter branded GLP-1 costs approaching or exceeding $1,000 per month. Those historical prices explain many older articles, but they no longer describe the entire 2026 cash-pay market.
There is no single national semaglutide price. The amount a patient pays depends on whether the prescription is for an FDA-approved branded product, a legally compounded preparation when compounding is permissible, the dose, pharmacy, insurance, manufacturer savings eligibility and whether a clinic bundles medical care into the monthly fee.
As one current Florida example, Padgett Medical Center publishes compounded semaglutide programs ranging from $149 per month at its lowest listed dose through $299 per month at higher listed doses, including consultation, medication, ongoing check-ins and delivery. Other clinics and telehealth programs may charge more, particularly when laboratory testing, frequent visits, nutrition services or other care is bundled into the price.
When demand for GLP-1 medications surged and branded supply was constrained, uninsured retail pricing could be extremely high. NovaGenix's original version of this article reflected that earlier market and cited costs around $1,000–$1,500 per month.
The market has changed. Manufacturer direct-to-patient pricing, broader competition and cash-pay clinic programs mean that a four-figure monthly estimate is no longer a useful description of what every self-pay patient will encounter.
Novo Nordisk's NovoCare program currently lists standard self-pay pricing of $349 per month for Wegovy injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. Wegovy HD 7.2 mg is listed at $399 per month.
Eligible new self-pay patients may qualify for limited introductory pricing of $199 per month for the first two monthly fills of the 0.25 mg and 0.5 mg injection doses, after which standard pricing applies. Offers, eligibility rules and prices can change, so patients should verify current terms directly with the manufacturer.
Some clinics advertise semaglutide programs below branded Wegovy self-pay pricing. Current published examples demonstrate why a reasonable market discussion should include prices from roughly the mid-$100s through several hundred dollars per month rather than quoting one universal figure.
Compounded semaglutide is not FDA-approved and should not be described as generic Wegovy or as equivalent to an FDA-approved product. Compounding rules and availability can change, and prescriptions must comply with applicable federal and state law.
Headline prices are often not directly comparable. A monthly program may include only medication, or it may bundle some combination of clinician visits, medication, syringes, shipping, laboratory testing, body-composition measurements, nutrition support and follow-up.
Dose also matters. Some programs advertise a low introductory price that increases as the prescribed dose rises. Others advertise one flat monthly fee. Before choosing a program, patients should ask what the price becomes at later doses and whether there are enrollment, refill, shipping or cancellation fees.
Do not judge a GLP-1 program by the advertised starting price alone. Some advertisements highlight an introductory or low-dose price even though semaglutide treatment may involve gradual dose titration. If a program uses dose-based pricing, the monthly charge can increase as the prescribed dose increases.
Before enrolling, look beyond testimonials displayed on the provider's own website. Review recent feedback on independent platforms and look for recurring comments about unexpected dose increases, membership fees, refill charges, shipping, laboratory costs, cancellation problems, customer service and whether the advertised price remained available after the introductory period.
A low introductory price is not automatically deceptive—there may be legitimate clinical and pharmacy reasons for dose-based pricing—but the full pricing structure should be disclosed clearly before enrollment. Patients should ask for the price at every anticipated dose, what services are included, what costs extra, whether prepayment is required and what happens if treatment is stopped.
Coverage depends heavily on the exact product, indication and health plan. Ozempic is an FDA-approved semaglutide product for type 2 diabetes with additional labeled cardiovascular and kidney-related indications in appropriate patients; it is not FDA-approved simply for weight loss. Wegovy is the semaglutide product with FDA-approved chronic weight-management indications for eligible patients and additional labeled indications.
Some commercial plans cover Wegovy, others exclude anti-obesity medications, and prior authorization is common. Patients should check the specific drug formulary rather than assume that “semaglutide” is either universally covered or universally excluded.
Yes. For eligible commercially insured patients whose plan covers Wegovy, Novo Nordisk currently advertises savings that can reduce the patient's out-of-pocket cost substantially, subject to eligibility and program limits.
Conversely, a patient whose plan excludes obesity medication may find a transparent cash-pay program more predictable. The lowest sticker price is not always the lowest total cost after insurance rules, deductibles and program fees are considered.
Both products contain semaglutide but have different FDA-approved indications, dosing and pricing programs. Patients should not select Ozempic solely because an advertisement suggests it is a cheaper version of Wegovy. The prescribed product should match the medical indication and treatment plan.
It can be, based on published cash-pay clinic prices, but price is only one consideration. Compounded drugs do not undergo FDA premarket review for safety, effectiveness or manufacturing quality in the same way FDA-approved drugs do. Patients should understand why a compounded product is being prescribed, where it is dispensed and how current compounding rules apply.
There is no standard national consultation fee. Some clinics include medical evaluation in the monthly price; others charge separately. A higher total fee may be reasonable when it includes substantive physician evaluation, laboratory review and ongoing follow-up, while a low headline price may become more expensive after add-on fees.
A $99 or $149 advertisement may represent only the starting dose, the first month, a multi-month prepaid plan or medication without medical services. A $399–$499 program may include substantially more care—or it may simply be more expensive. Patients should compare the same components before deciding which represents better value.
If the advertised price applies only to a starter dose, ask what months two, three, four and beyond are expected to cost under the provider's normal titration schedule. Comparing the estimated total cost over several months is usually more meaningful than comparing first-month advertisements.
Not necessarily. Four-figure retail pricing remains part of semaglutide's historical and list-price story, but manufacturer self-pay offers and cash-pay clinic programs have substantially changed what many patients can actually pay in 2026.
Published clinic pricing varies widely. Current examples can begin around $150 per month, commonly move into the $200–$400 range, and some bundled physician-supervised programs can reach $400–$500 or more. What is included matters as much as the headline price.
NovoCare currently lists standard Wegovy injection self-pay pricing at $349 per month for conventional doses and $399 per month for Wegovy HD, with certain limited introductory offers for eligible new patients.
Often. Some clinic programs charge progressively more at higher doses, while others use flat pricing. Patients should ask for the full dose-based schedule before enrolling.
Ask for the complete written price schedule before paying. Confirm dose-based increases, membership and refill fees, labs, shipping, supplies, consultation charges, minimum commitments and cancellation terms. Independent reviews can also reveal whether other patients consistently encountered charges that were not obvious from the headline advertisement.
No. Wegovy is an FDA-approved branded semaglutide product. A compounded semaglutide preparation is not FDA-approved and should not be represented as generic or equivalent Wegovy.
NovaGenix can explain what is included in its medical weight-management programs and discuss which options may be appropriate based on medical history and treatment goals. Learn about Dr. Timothy Mackey, visit About NovaGenix, or review our weight-loss programs.
Call 561-277-8260 | Text NovaGenix | Schedule a Consultation
Prices and manufacturer offers change. Figures above were reviewed in September 2026 and should be verified before making a purchasing or treatment decision. This article is educational and does not replace individualized medical advice.
Speak with NovaGenix about physician-led evaluation, testing, and treatment options in Jupiter, Florida.
Medical disclaimer: This article is for general educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Reading it does not create a physician-patient relationship. Always consult a qualified healthcare professional about your individual circumstances, and never delay seeking care because of something you read here. If you are experiencing a medical emergency, call 911. Read our full Medical Disclaimer.


609 N Hepburn avenue suite 106. Jupiter, Florida 33458
609 N Hepburn avenue suite 106. Jupiter, Florida 33458
561-277-8260
Learn what you want to know about hormone therapy by scheduling a free consultation.
Contact Us Today609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed